At the end of the 6-month intervention, among the 310 participants with ≥ 2 MetS components at baseline, a larger proportion of participants in the SADA group had ≥ 2 MetS components reversed than those in the SAA group (28.2% vs. This evidence concerns the gene BRSK2 and metabolic syndrome.